Completed OBSERVATIONAL NCT01197729

OPTAMI (Optimized Therapy of Acute Myocardial Infarction) - Registry (OPTAMI)

OPTAMI (Optimierte Therapie Des Akuten Myokard-Infarktes) - Register

Sponsor: GlaxoSmithKline

Conditions Myocardial Infarction Non-ST-Elevation Myocardial Infarction ST-Elevation Myocardial Infarction

Updated 7 times since 2017 Last updated: Dec 18, 2024 Started: Oct 31, 2005 Primary completion: Feb 28, 2009 Completion: Feb 28, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This observational or N/A phase trial investigates Myocardial Infarction and Non-ST-Elevation Myocardial Infarction and is currently completed. GlaxoSmithKline leads this study, which shows 7 recorded versions since 2005 — indicating limited longitudinal coverage. Heart and vascular conditions benefit from the kind of long-term tracking this trial provides.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed
Jan 2025 — Sep 2025 [monthly]

Completed
Sep 2024 — Jan 2025 [monthly]

Completed
Jul 2024 — Sep 2024 [monthly]

Completed
Jan 2021 — Jul 2024 [monthly]

Completed

▶ Show 2 earlier versions

Apr 2018 — Jan 2021 [monthly]

Completed

Phase: NA → None
Jan 2017 — Apr 2018 [monthly]

Completed NA

First recorded

Oct 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

GlaxoSmithKline
Klinikum Nürnberg
Stiftung Institut fuer Herzinfarktforschung
University Hospital Muenster

Data source: Stiftung Institut fuer Herzinfarktforschung

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Münster, Germany
• Nuremberg, Germany